Kenvue Inc. (NYSE:KVUE) Shares Sold by Procyon Advisors LLC

Procyon Advisors LLC reduced its stake in Kenvue Inc. (NYSE:KVUE) by 78.7% in the fourth quarter, HoldingsChannel reports. The fund owned 13,772 shares of the company’s stock after selling 50,865 shares during the quarter. Procyon Advisors LLC’s holdings in Kenvue were worth $294,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Leo Wealth LLC boosted its position in shares of Kenvue by 0.3% during the 3rd quarter. Leo Wealth LLC now owns 151,611 shares of the company’s stock valued at $3,507,000 after purchasing an additional 481 shares in the last quarter. Alerus Financial NA lifted its stake in Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company’s stock valued at $4,426,000 after purchasing an additional 491 shares during the last quarter. Massmutual Trust Co. FSB ADV boosted its holdings in Kenvue by 6.2% during the third quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company’s stock worth $194,000 after buying an additional 492 shares in the last quarter. Wolff Wiese Magana LLC boosted its holdings in Kenvue by 0.7% during the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after buying an additional 501 shares in the last quarter. Finally, Marathon Capital Management grew its position in Kenvue by 0.3% in the second quarter. Marathon Capital Management now owns 149,699 shares of the company’s stock worth $2,722,000 after buying an additional 514 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

NYSE KVUE opened at $21.11 on Monday. The company has a 50 day moving average price of $22.42 and a two-hundred day moving average price of $21.71. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.46. The stock has a market capitalization of $40.46 billion, a PE ratio of 38.37, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The firm had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same period in the prior year, the company posted $0.31 earnings per share. Kenvue’s revenue for the quarter was down .4% on a year-over-year basis. As a group, equities analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a $0.205 dividend. The ex-dividend date is Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.89%. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft lowered Kenvue from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Bank of America boosted their price objective on Kenvue from $24.00 to $27.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. JPMorgan Chase & Co. raised their target price on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Barclays cut their price target on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday. Finally, UBS Group decreased their price objective on shares of Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a research note on Thursday. One analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $23.08.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.